NCT03500380 2024-02-20
A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases
RemeGen Co., Ltd.
Phase 2/3 Unknown
Clinical Trials
4 trialsNCT03085368 2017-07-28
A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin
Peking Union Medical College Hospital
Phase 2/3 Unknown
NCT00450203 2016-12-01
ST03
Medical Research Council
Phase 2/3 Unknown
NCT01426880 2016-02-15
GeparSixto
GBG Forschungs GmbH
Phase 2/3 Completed